RSS   Newsletter   Contact   Advertise with us

Merrimack Pharma names Sergio Santillana as CMO

Staff Writer | Cambridge, Mass., USA | June 9, 2017
Merrimack PharmaceuticalsJune 9, 2017, Cambridge, Mass., USA - Merrimack Pharmaceuticals, a biopharmaceutical company, announced that Sergio L. Santillana has been appointed to the role of chief medical officer, effective June 12, 2017.
Mr. Santillana, M.D., MSc, previously served as Chief Medical Officer at ARIAD Pharmaceuticals, a commercial-stage biotechnology company acquired by Takeda Pharmaceuticals earlier this year.

Prior to joining ARIAD, Dr. Santillana served in various oncology clinical development leadership roles at Takeda, GlaxoSmithKline and Eli Lilly.

Before entering the biopharma industry, he was a practicing board-certified medical oncologist for 15 years, including tenure at the National Cancer Institute of Peru (INEN).

Dr. Santillana holds an M.S. in Experimental Therapeutics from Kellogg College at the University of Oxford and an M.D. and B.S. from the Universidad Nacional Federico Villarreal School of Medicine.

Ellen K. Forest, who served most recently as Director of Human Resources at Baxalta, has joined Merrimack to lead its talent and recruitment strategy as the new Head of Human Resources.

Ms. Forest served as Director of Human Resources at Baxalta, a global biopharmaceutical company and spin-off of Baxter International, until the company was acquired by Shire in 2016.

Previously, Ms. Forest held leadership positions in Human Resources at Partners HealthCare System, the hospital system affiliated with Harvard Medical School; Dovetail Health, a home healthcare company; and TA Associates, a global private equity firm.

Ms. Forest holds an M.S. in Human Resources Management and a B.S. from Emmanuel College.


 LATEST MOVES FROM Massachusetts 


MORE INSIDE POST